ArticleJournal of managed care & specialty pharmacy2024

Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective.

Stephen Chaplin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.